Expanding Horizons in the Therapeutic Landscape for Relapsed Ovarian Cancer

MEETING OVERVIEW

We are pleased to invite you to join us on 28 September 2012 forExpanding Horizons in the Therapeutic Landscape for Relapsed Ovarian Cancer, an ESMO Vienna 2012 Industry Satellite Symposium to be held on 28 September 2012 in Vienna, Austria.

AGENDA

12.30		Welcome and introduction Ignace Vergote, MD, PhD
12.35		Clinical opinion poll
12.40		The pathogenesis of relapsed ovarian cancer: Defining new targets Robert Coleman, MD
13.00		Clinical opinion poll
13.05		Platinum-sensitive, relapsed ovarian cancer: A look to the future Nicoletta Colombo, MD
13.25		Clinical opinion poll
13.30		How can we improve treatment of platinum-resistant/refractory disease? Thomas Herzog, MD
13.45		Ask the experts All Faculty
13.55		Closing comments Ignace Vergote, MD, PhD

FACULTY

• CHAIR

  • Ignace Vergote, MD, PhD
    University Hospital Gasthuisberg
    Leuven, European Union

• FACULTY

  • Robert Coleman, MD
    University of Texas 
    M. D. Anderson Cancer Center
    Houston, Texas, United States
  • Nicoletta Colombo, MD
    University of Milan-Bicocca
    Milan, Italy
  • Thomas Herzog, MD
    Columbia University Medical Center
    New York, New York, United States

TARGET AUDIENCE

This educational activity is specifically designed for medical oncologists, surgical oncologists, gynecologic oncologists, and other healthcare professionals interested and/or involved in the treatment of patients with ovarian cancer.

LEARNING OBJECTIVES

After successful completion of this educational activity, participants should be able to:

• Describe the rationale and mechanisms of action for novel therapies in patients with relapsed ovarian cancer as it relates to disease pathogenesis
• Examine current and emerging treatment options for patients with platinum-sensitive ovarian cancer, including integration of novel targeted agents
• Discuss optimal treatment approaches for patients with platinum-resistant/refractory ovarian cancer based on patient and disease characteristics
• Evaluate strategies for improving the overall treatment of patients with relapsed ovarian cancer, including treatment individualization, biomarker use, and multidisciplinary management

http://www.primeoncology.org/live_education/solid_tumor/ovarian_2012_vienna.aspx

Sent from my iPhone